SCHEMBL3603750

SCHEMBL3603750

N=C(N)Nc1nc(-c2cccc(C(N)=O)c2)cs1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
GAA P10253 3/20 0.55
NPSR1 Q6W5P4 1/20 0.55
ABL1 P00519 3/20 0.54
ALDH1A1 P00352 4/20 0.51
HTT P42858 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
SCD O00767 1/20 0.51
HPGD P15428 1/20 0.51
HSD17B10 Q99714 1/20 0.51
RRM1 P23921 1/20 0.51
RRM2B Q7LG56 1/20 0.51
GSTO1 P78417 1/20 0.50
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3606683 0.91 CSNK2A1 (0.58) MAPTNPC1RAB9AGAANPSR1
Bromide SCHEMBL7142457 0.90 CSNK2A1 (0.57) MAPTNPC1RAB9AGAANPSR1
SCHEMBL11090239 0.89 MAPT (0.51) MAPTNPC1RAB9AGAANPSR1
SCHEMBL11091588 0.89 MAPT (0.55) MAPTNPC1RAB9AGAANPSR1
SCHEMBL3609767 0.88 PHGDH (0.55) MAPTNPC1RAB9AGAANPSR1
SCHEMBL11087776 0.88 ALDH1A1 (0.56) MAPTNPC1RAB9AGAANPSR1
SCHEMBL11090908 0.87 MAPT (0.50) MAPTNPC1RAB9AGAANPSR1
SCHEMBL11093012 0.86 GAA (0.48) MAPTNPC1RAB9AGAANPSR1
SCHEMBL11093016 0.86 MAPT (0.48) MAPTNPC1RAB9AGAANPSR1
SCHEMBL11090915 0.86 MAPT (0.49) MAPTNPC1RAB9AGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP claimed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed
US-4452985-A 2-Guanyl-4-(substituted phenyl) thiazole derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1984-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 MAPT 2/4885NPC1 267/4885RAB9A 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.